Clinical Trial Update: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML [Phase 2]

View source ↗

Summary

Clinical trial update on RVU120 for relapsed/refractory acute myeloid leukemia in a Phase 2 study. The trial is currently active but not recruiting, with safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome

Drugs mentioned

• RVU-120 (RVU120)

Snippet

Sponsor: Ryvu Therapeutics SA | Conditions: Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING